<p>Abeona Therapeutics（纳斯达克股票代码：ABEO - 获取免费报告）在周五发布的研究报告中，Oppenheimer 的投资分析师将其目标价格从 19.00 美元上调至 20.00 美元。该公司目前对这家生物制药公司的股票给予 “跑赢大盘” 的评级。Oppenheimer 的目标价格暗示该股票当前价格有 177.93% 的潜在上涨空间。</p>
<p>其他一些分析师也最近对该公司发表了看法。华尔街 Zen 在 5 月 15 日的研究报告中将 Abeona Therapeutics 的评级从 “持有” 下调至 “卖出”。Alliance Global Partners 在 5 月 15 日的研究报告中重申了对 Abeona Therapeutics 股票的 “买入” 评级。Stifel Nicolaus 在 5 月 16 日的研究报告中将 Abeona Therapeutics 的目标价格从 21.00 美元下调至 20.00 美元，并对该股票给予 “买入” 评级。最后，HC Wainwright 在 7 月 14 日的研究报告中重申了 “买入” 评级，并对 Abeona Therapeutics 的股票设定了 20.00 美元的目标价格。一位研究分析师对该股票给予了 “卖出” 评级，五位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，Abeona Therapeutics 目前的共识评级为 “适度买入”，平均目标价格为 19.50 美元。</p>
<p>获取 <strong>Abeona Therapeutics</strong> 的提醒：</p>
<p><strong>阅读我们关于 ABEO 的最新研究报告</strong></p>
<h2>Abeona Therapeutics 股票下跌 0.5%</h2>
<p>在周五的午盘交易中，纳斯达克：ABEO 下跌 0.03 美元，达到 7.20 美元。该公司的交易量为 443,058 股，而其平均交易量为 1,024,247 股。该公司的市值为 3.6815 亿美元，市盈率为-5.70，贝塔值为 1.55。该股票的 50 日简单移动平均线为 6.23 美元，200 日简单移动平均线为 5.73 美元。Abeona Therapeutics 的 12 个月低点为 3.93 美元，12 个月高点为 7.54 美元。该公司的流动比率为 4.90，速动比率为 4.90，债务与股本比率为 0.27。</p>
<p>Abeona Therapeutics（纳斯达克：ABEO - 获取免费报告）最近于 8 月 14 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为 1.71 美元，超出分析师的共识预期（-0.39 美元）2.10 美元。该公司本季度的收入为 40 万美元，而分析师的预期为 2171 万美元。平均而言，卖方分析师预计 Abeona Therapeutics 在本财年将发布-1.16 美元的每股收益。</p>
<h2>Abeona Therapeutics 的内部买卖</h2>
<p>在其他消息中，首席财务官 Joseph Walter Vazzano 在 7 月 9 日的交易中出售了 25,411 股 Abeona Therapeutics 的股票。该股票以平均价格 5.86 美元出售，总交易额为 148,908.46 美元。出售后，首席财务官在公司持有 479,168 股，价值约为 2,807,924.48 美元。此次交易使其持股比例减少了 5.04%。该交易在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，董事 Faith L. Charles 在 7 月 9 日的交易中出售了 10,738 股 Abeona Therapeutics 的股票。该股票以平均价格 5.86 美元出售，总价值为 62,924.68 美元。出售后，该董事在公司持有 139,094 股，价值为 815,090.84 美元。此次交易使其持股比例减少了 7.17%。该交易的披露信息可以在这里找到。在过去三个月中，内部人士已出售 231,626 股公司股票，价值为 1,430,587 美元。6.90% 的股票由内部人士持有。</p>
<h2>Abeona Therapeutics 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。法国巴黎银行金融市场在第二季度收购了 Abeona Therapeutics 的新股份，价值约为 749,000 美元。Boone Capital Management LLC 在第二季度收购了 Abeona Therapeutics 的新股份，价值约为 7,126,000 美元。美国银行在第二季度将其在 Abeona Therapeutics 的持仓增加了 154.9%。美国银行目前持有 329,884 股该生物制药公司的股票，价值为 1,874,000 美元，此前在上个季度又购买了 200,469 股。683 Capital Management LLC 在第二季度将其在 Abeona Therapeutics 的持仓增加了 11.1%。683 Capital Management LLC 目前持有 750,000 股该生物制药公司的股票，价值为 4,260,000 美元，此前在此期间又收购了 75,000 股。最后，Adage Capital Partners GP L.L.C.在第二季度将其在 Abeona Therapeutics 的持仓增加了 14.2%。Adage Capital Partners GP L.L.C.目前持有 3,072,985 股该生物制药公司的股票，价值为 17,455,000 美元，此前在此期间又收购了 381,357 股。机构投资者和对冲基金持有该公司 80.56% 的股票。</p>
<h2>关于 Abeona Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Abeona Therapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和提供针对严重和危及生命的罕见疾病的基因治疗产品。该公司的主要项目包括 EB-101（基因修正的皮肤移植）用于隐性营养不良性表皮松解症（RDEB）；ABO-102，基于 AAV 的基因治疗用于 A 型 Sanfilippo 综合症；以及 ABO-101，基于腺病毒相关病毒（AAV）的基因治疗用于 B 型 Sanfilippo 综合症。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Abeona Therapeutics 更好</li>
<li>3 只 REITs 值得长期买入和持有</li>
<li>Arista Networks：作为 AI 流量的收费站而获利</li>
<li>每月分红股票的利与弊</li>
<li>Elbit Systems 因创纪录的收益和 16 亿美元的合同而上涨</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>Microchip Technologies 有望实现宏观反转和反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Abeona Therapeutics 吗？</h2>
<p>在考虑 Abeona Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Abeona Therapeutics 并不在名单上。</p>
<p>虽然 Abeona Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Abeona治疗

<p>Oppenheimer 已将 Abeona Therapeutics（NASDAQ:ABEO）的目标股价从 19.00 美元上调至 20.00 美元，维持 “跑赢大盘” 的评级。这表明相较于当前股价 7.20 美元，潜在上涨幅度为 177.93%。其他分析师的观点不一，其中一位将该股票评级下调至 “卖出”，而其他分析师则维持 “买入” 评级。Abeona 最近的财报显示每股收益大幅超出预期，但收入未能达到预期。此外，还注意到内部交易活动，首席财务官和董事最近出售了股份</p>

<p>Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) had its price objective boosted by investment analysts at Oppenheimer from $19.00 to $20.00 in a research note issued on Friday,Benzinga reports. The firm presently has an &#34;outperform&#34; rating on the biopharmaceutical company's stock. Oppenheimer's target price would suggest a potential upside of 177.93% from the stock's current price.</p>
<div class="lb-trans"><p>Abeona Therapeutics（纳斯达克股票代码：ABEO - 获取免费报告）在周五发布的研究报告中，Oppenheimer 的投资分析师将其目标价格从 19.00 美元上调至 20.00 美元。该公司目前对这家生物制药公司的股票给予 “跑赢大盘” 的评级。Oppenheimer 的目标价格暗示该股票当前价格有 177.93% 的潜在上涨空间。</p>
</div><p>A number of other analysts have also recently weighed in on the company. Wall Street Zen cut Abeona Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Thursday, May 15th. Alliance Global Partners restated a &#34;buy&#34; rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Stifel Nicolaus cut their price target on Abeona Therapeutics from $21.00 to $20.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, May 16th. Finally, HC Wainwright restated a &#34;buy&#34; rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, July 14th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Abeona Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $19.50.</p>
<div class="lb-trans"><p>其他一些分析师也最近对该公司发表了看法。华尔街 Zen 在 5 月 15 日的研究报告中将 Abeona Therapeutics 的评级从 “持有” 下调至 “卖出”。Alliance Global Partners 在 5 月 15 日的研究报告中重申了对 Abeona Therapeutics 股票的 “买入” 评级。Stifel Nicolaus 在 5 月 16 日的研究报告中将 Abeona Therapeutics 的目标价格从 21.00 美元下调至 20.00 美元，并对该股票给予 “买入” 评级。最后，HC Wainwright 在 7 月 14 日的研究报告中重申了 “买入” 评级，并对 Abeona Therapeutics 的股票设定了 20.00 美元的目标价格。一位研究分析师对该股票给予了 “卖出” 评级，五位分析师给予了 “买入” 评级。根据 MarketBeat 的数据，Abeona Therapeutics 目前的共识评级为 “适度买入”，平均目标价格为 19.50 美元。</p>
</div><p>Get <strong>Abeona Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Abeona Therapeutics</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Research Report on ABEO</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ABEO 的最新研究报告</strong></p>
</div><h2>Abeona Therapeutics Stock Down 0.5%</h2>
<div class="lb-trans"><h2>Abeona Therapeutics 股票下跌 0.5%</h2>
</div><p>NASDAQ:ABEO traded down $0.03 during midday trading on Friday, reaching $7.20. The company had a trading volume of 443,058 shares, compared to its average volume of 1,024,247. The firm has a market capitalization of $368.15 million, a price-to-earnings ratio of -5.70 and a beta of 1.55. The stock's fifty day simple moving average is $6.23 and its 200-day simple moving average is $5.73. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.54. The company has a current ratio of 4.90, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27.</p>
<div class="lb-trans"><p>在周五的午盘交易中，纳斯达克：ABEO 下跌 0.03 美元，达到 7.20 美元。该公司的交易量为 443,058 股，而其平均交易量为 1,024,247 股。该公司的市值为 3.6815 亿美元，市盈率为-5.70，贝塔值为 1.55。该股票的 50 日简单移动平均线为 6.23 美元，200 日简单移动平均线为 5.73 美元。Abeona Therapeutics 的 12 个月低点为 3.93 美元，12 个月高点为 7.54 美元。该公司的流动比率为 4.90，速动比率为 4.90，债务与股本比率为 0.27。</p>
</div><p>Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to analysts' expectations of $21.71 million. On average, sell-side analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Abeona Therapeutics（纳斯达克：ABEO - 获取免费报告）最近于 8 月 14 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为 1.71 美元，超出分析师的共识预期（-0.39 美元）2.10 美元。该公司本季度的收入为 40 万美元，而分析师的预期为 2171 万美元。平均而言，卖方分析师预计 Abeona Therapeutics 在本财年将发布-1.16 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Abeona Therapeutics</h2>
<div class="lb-trans"><h2>Abeona Therapeutics 的内部买卖</h2>
</div><p>In other news, CFO Joseph Walter Vazzano sold 25,411 shares of Abeona Therapeutics stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $148,908.46. Following the sale, the chief financial officer owned 479,168 shares in the company, valued at approximately $2,807,924.48. The trade was a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, Director Faith L. Charles sold 10,738 shares of Abeona Therapeutics stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $62,924.68. Following the sale, the director owned 139,094 shares in the company, valued at $815,090.84. This trade represents a 7.17% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 231,626 shares of company stock valued at $1,430,587. 6.90% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Joseph Walter Vazzano 在 7 月 9 日的交易中出售了 25,411 股 Abeona Therapeutics 的股票。该股票以平均价格 5.86 美元出售，总交易额为 148,908.46 美元。出售后，首席财务官在公司持有 479,168 股，价值约为 2,807,924.48 美元。此次交易使其持股比例减少了 5.04%。该交易在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，董事 Faith L. Charles 在 7 月 9 日的交易中出售了 10,738 股 Abeona Therapeutics 的股票。该股票以平均价格 5.86 美元出售，总价值为 62,924.68 美元。出售后，该董事在公司持有 139,094 股，价值为 815,090.84 美元。此次交易使其持股比例减少了 7.17%。该交易的披露信息可以在这里找到。在过去三个月中，内部人士已出售 231,626 股公司股票，价值为 1,430,587 美元。6.90% 的股票由内部人士持有。</p>
</div><h2>Institutional Trading of Abeona Therapeutics</h2>
<div class="lb-trans"><h2>Abeona Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in shares of Abeona Therapeutics during the second quarter worth about $749,000. Boone Capital Management LLC acquired a new stake in shares of Abeona Therapeutics during the second quarter worth about $7,126,000. Bank of America Corp DE increased its position in shares of Abeona Therapeutics by 154.9% during the second quarter. Bank of America Corp DE now owns 329,884 shares of the biopharmaceutical company's stock worth $1,874,000 after purchasing an additional 200,469 shares in the last quarter. 683 Capital Management LLC increased its position in Abeona Therapeutics by 11.1% in the 2nd quarter. 683 Capital Management LLC now owns 750,000 shares of the biopharmaceutical company's stock valued at $4,260,000 after acquiring an additional 75,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in Abeona Therapeutics by 14.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company's stock valued at $17,455,000 after acquiring an additional 381,357 shares during the period. Institutional investors and hedge funds own 80.56% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。法国巴黎银行金融市场在第二季度收购了 Abeona Therapeutics 的新股份，价值约为 749,000 美元。Boone Capital Management LLC 在第二季度收购了 Abeona Therapeutics 的新股份，价值约为 7,126,000 美元。美国银行在第二季度将其在 Abeona Therapeutics 的持仓增加了 154.9%。美国银行目前持有 329,884 股该生物制药公司的股票，价值为 1,874,000 美元，此前在上个季度又购买了 200,469 股。683 Capital Management LLC 在第二季度将其在 Abeona Therapeutics 的持仓增加了 11.1%。683 Capital Management LLC 目前持有 750,000 股该生物制药公司的股票，价值为 4,260,000 美元，此前在此期间又收购了 75,000 股。最后，Adage Capital Partners GP L.L.C.在第二季度将其在 Abeona Therapeutics 的持仓增加了 14.2%。Adage Capital Partners GP L.L.C.目前持有 3,072,985 股该生物制药公司的股票，价值为 17,455,000 美元，此前在此期间又收购了 381,357 股。机构投资者和对冲基金持有该公司 80.56% 的股票。</p>
</div><h2>About Abeona Therapeutics</h2>
<div class="lb-trans"><h2>关于 Abeona Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.</p>
<div class="lb-trans"><p>Abeona Therapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和提供针对严重和危及生命的罕见疾病的基因治疗产品。该公司的主要项目包括 EB-101（基因修正的皮肤移植）用于隐性营养不良性表皮松解症（RDEB）；ABO-102，基于 AAV 的基因治疗用于 A 型 Sanfilippo 综合症；以及 ABO-101，基于腺病毒相关病毒（AAV）的基因治疗用于 B 型 Sanfilippo 综合症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Abeona Therapeutics</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Arista Networks: Cashing In as the Tollbooth for AI Traffic</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Elbit Systems Jumps on Record Earnings and a $1.6B Contract</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Microchip Technologies on Track for Macro Reversal and Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Abeona Therapeutics 更好</li>
<li>3 只 REITs 值得长期买入和持有</li>
<li>Arista Networks：作为 AI 流量的收费站而获利</li>
<li>每月分红股票的利与弊</li>
<li>Elbit Systems 因创纪录的收益和 16 亿美元的合同而上涨</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>Microchip Technologies 有望实现宏观反转和反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ABEO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abeona Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Abeona Therapeutics 吗？</h2>
</div><p>Before you consider Abeona Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Abeona Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Abeona Therapeutics 并不在名单上。</p>
</div><p>While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Abeona Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oppenheimer 将 Abeona 治疗（NASDAQ:ABEO）的目标股价上调至 20.00 美元